Please assess the completion status of the following clinical trial:

Trial Title: Effects of Caffeine on Intermittent Hypoxia in Infants Born Preterm

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Gestational age of 25 + 0 to 32 + 0 weeks PMA at birth, and 34 + 0 to 375 + 6 weeks PMA at randomization~2. Prior treatment with caffeine based on routine clinical indications, and clinical caffeine now discontinued ≥5 days before randomization~3. Previously tolerated clinical treatment with caffeine~4. Breathing room air (no current supplemental O2 treatment; may have previously required respiratory support)~5. Parental consent to enroll in pilot study~Exclusion Criteria:~1. Congenital syndrome or other medical diagnosis associated with known risk for neurodevelopmental abnormality, including intraventricular hemorrhage Grade 3 or greater, cyanotic congenital heart disease, confirmed central nervous system infection, or fetal alcohol syndrome~2. Currently receiving supplemental oxygen, ventilatory support, or nasal airflow therapy~3. Clinical decision to restart caffeine prior to completing 5 days of continuous physiologic monitoring after clinical caffeine stopped~4. Anticipated inability to meet protocol requirements

- Gender: ALL
- Minimum Age: 33 Weeks
- Maximum Age: 37 Weeks
- Healthy Volunteers: f

Study Arms:
- Caffeine (Type: EXPERIMENTAL): Caffeine citrate 6 mg/kg/day
- Active Comparator: no caffeine (Type: NO_INTERVENTION): Compare extended use of caffeine citrate 6 mg/kg/day to no caffeine (usual care) in regard to extent of intermittent hypoxia from 35 weeks postmenstrual age (PMA) to 40 weeks PMA.

Based on this trial design, predict the completion outcome and termination type (if applicable).